Saltar al contenido
Merck
Todas las fotos(2)

Key Documents

View All Documentation

325767

Sigma-Aldrich

Lanthanum(III) carbonate hydrate

99.9% trace metals basis

Sinónimos:

Fosrenol, Lanthanum(3+) tricarbonate hydrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(2)

About This Item

Fórmula lineal:
La2(CO3)3·xH2O
Número de CAS:
54451-24-0
Peso molecular:
457.84 (anhydrous basis)
EC Number:
209-599-5
MDL number:
MFCD00149757
UNSPSC Code:
12352302
PubChem Substance ID:
24859532
NACRES:
NA.23

assay

99.9% trace metals basis

form

powder

composition

Degree of hydration, 2-5

reaction suitability

reagent type: catalyst
core: lanthanum

impurities

≤1500.0 ppm Trace Rare Earth Analysis

SMILES string

O.[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O

InChI

1S/3CH2O3.2La.H2O/c3*2-1(3)4;;;/h3*(H2,2,3,4);;;1H2/q;;;2*+3;/p-6

InChI key

AFCUGQOTNCVYSW-UHFFFAOYSA-H

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

nwg

ppe

dust mask type N95 (US), Eyeshields, Gloves

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
MKCK6773
MKCJ1347
MKCG2307
MKCF9267
MKCC3328

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Reiko Inoue et al.
Clinical and experimental nephrology, 23(6), 859-864 (2019-03-02)
This study aims to describe the regional variance in prescriptions for chronic kidney disease (CKD) medications and to analyze regional characteristics to identify the sources of these differences by utilizing the National Database of Health Insurance Claims, which provides more
Stefan P Schumacher et al.
Nephrology (Carlton, Vic.), 24(2), 221-226 (2018-02-27)
Hyperphosphataemia is associated with increased mortality and morbidity in end stage renal disease. Despite phosphate binder therapy, a large proportion of patients do not reach the treatment target. In five contemporary binders we explored the influence of pH and phosphate
Atsushi Yaguchi et al.
PloS one, 12(7), e0180430-e0180430 (2017-07-14)
The effects of PA21, a novel iron-based and non-calcium-based phosphate binder, on hyperphosphatemia and its accompanying bone abnormality in chronic kidney disease-mineral and bone disorder (CKD-MBD) were evaluated. Rats with adenine-induced chronic renal failure (CRF) were prepared by feeding them
Olivier Phan et al.
BioMed research international, 2015, 515606-515606 (2015-07-30)
Elevated serum phosphorus, calcium, and fibroblast growth factor 23 (FGF23) levels are associated with cardiovascular disease in chronic renal disease. This study evaluated the effects of sucroferric oxyhydroxide (PA21), a new iron-based phosphate binder, versus lanthanum carbonate (La) and sevelamer

Artículos

Thermoelectric Performance of Perovskite-type Oxide Materials

The prevailing strategies for heat and electric-power production that rely on fossil and fission fuels are having a negative impact on the environment and on our living conditions.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico